Swedbank AB Has $114.64 Million Holdings in Amgen Inc. $AMGN

Swedbank AB cut its position in shares of Amgen Inc. (NASDAQ:AMGN) by 19.7% during the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 325,833 shares of the medical research company’s stock after selling 79,726 shares during the period. Swedbank AB’s holdings in Amgen were worth $114,644,000 at the end of the most recent reporting period.

Other large investors have also modified their holdings of the company. Brighton Jones LLC increased its stake in Amgen by 23.5% in the fourth quarter. Brighton Jones LLC now owns 27,468 shares of the medical research company’s stock valued at $7,159,000 after acquiring an additional 5,226 shares during the period. Sivia Capital Partners LLC lifted its stake in Amgen by 10.6% during the second quarter. Sivia Capital Partners LLC now owns 1,186 shares of the medical research company’s stock worth $331,000 after purchasing an additional 114 shares during the period. Schnieders Capital Management LLC. boosted its holdings in Amgen by 29.3% during the second quarter. Schnieders Capital Management LLC. now owns 25,859 shares of the medical research company’s stock valued at $7,220,000 after purchasing an additional 5,853 shares in the last quarter. Main Street Financial Solutions LLC boosted its holdings in Amgen by 11.3% during the second quarter. Main Street Financial Solutions LLC now owns 4,086 shares of the medical research company’s stock valued at $1,141,000 after purchasing an additional 416 shares in the last quarter. Finally, Ieq Capital LLC grew its stake in shares of Amgen by 5.1% in the 2nd quarter. Ieq Capital LLC now owns 54,152 shares of the medical research company’s stock valued at $15,120,000 after purchasing an additional 2,611 shares during the period. 76.50% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Several equities analysts recently commented on the company. BMO Capital Markets restated an “outperform” rating and set a $400.00 target price on shares of Amgen in a research report on Wednesday, July 1st. Truist Financial upped their price target on Amgen from $327.00 to $340.00 and gave the company a “hold” rating in a research report on Tuesday. Weiss Ratings reiterated a “buy (b)” rating on shares of Amgen in a research note on Thursday, June 18th. Morgan Stanley lifted their price objective on Amgen from $332.00 to $340.00 and gave the company an “equal weight” rating in a report on Tuesday, June 9th. Finally, Piper Sandler restated an “overweight” rating on shares of Amgen in a research note on Friday, June 12th. Two equities research analysts have rated the stock with a Strong Buy rating, eleven have issued a Buy rating, fifteen have given a Hold rating and two have given a Sell rating to the company. According to MarketBeat.com, the stock has an average rating of “Hold” and a consensus price target of $356.00.

Insider Activity at Amgen

In other news, SVP Nancy A. Grygiel sold 1,237 shares of the business’s stock in a transaction on Monday, May 4th. The stock was sold at an average price of $323.73, for a total transaction of $400,454.01. Following the completion of the sale, the senior vice president owned 7,009 shares in the company, valued at $2,269,023.57. The trade was a 15.00% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Company insiders own 0.85% of the company’s stock.

Amgen Price Performance

AMGN opened at $368.10 on Wednesday. Amgen Inc. has a one year low of $269.77 and a one year high of $391.29. The company has a debt-to-equity ratio of 5.65, a current ratio of 1.26 and a quick ratio of 1.01. The company’s 50 day simple moving average is $343.26 and its 200-day simple moving average is $348.66. The stock has a market capitalization of $198.67 billion, a P/E ratio of 25.62, a price-to-earnings-growth ratio of 3.61 and a beta of 0.41.

Amgen (NASDAQ:AMGN) last posted its quarterly earnings data on Thursday, April 30th. The medical research company reported $5.15 earnings per share for the quarter, topping the consensus estimate of $4.77 by $0.38. Amgen had a net margin of 20.96% and a return on equity of 137.41%. The firm had revenue of $8.62 billion during the quarter, compared to analysts’ expectations of $8.58 billion. During the same quarter in the previous year, the company posted $4.90 EPS. Amgen’s revenue was up 5.8% on a year-over-year basis. Amgen has set its FY 2026 guidance at 21.700-23.100 EPS. Sell-side analysts anticipate that Amgen Inc. will post 22.39 earnings per share for the current fiscal year.

Key Headlines Impacting Amgen

Here are the key news stories impacting Amgen this week:

• Positive Sentiment: Amgen received an upgrade to Zacks Rank #2 (Buy), which signals improving earnings expectations and could help sentiment near term.
• Positive Sentiment: Biotech stocks may be getting a boost from a more favorable M&A backdrop, with Jim Cramer calling biotech “the hottest group in the market” and suggesting deal activity could accelerate.
• Positive Sentiment: Several analysts raised or reaffirmed price targets on AMGN, including Truist lifting its target to $340 and Cantor Fitzgerald reaffirming a neutral stance with a $350 target, which still reflects solid long-term value expectations.
• Neutral Sentiment: Commentary on Amgen’s dividend safety suggests investors are still weighing near-term headwinds against the company’s cash generation and payout profile.
• Negative Sentiment: Amgen initiated broad U.S. recalls of Sensipar and Corlanor tied to CGMP deviations and contamination concerns, raising quality-control questions across multiple lots and dosage strengths.
• Negative Sentiment: Ongoing scrutiny around Tavneos and pipeline uncertainty continue to weigh on the shares, as regulators challenge the drug’s approval and investors reassess future growth prospects.

Amgen Profile

Amgen Inc (NASDAQ: AMGN) is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen’s work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.

Amgen’s commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease.